Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies

Alexandra Dreyzin(National Cancer Institute), Nirali N. Shah(National Institutes of Health), Kara L. Davis(Stanford Medicine), Sneha Ramakrishna(Stanford University), Constance M. Yuan(National Cancer Institute), Terry J. Fry(University of Colorado Anschutz Medical Campus), Serifat Adebola(National Cancer Institute), Grégoire Altan‐Bonnet(National Cancer Institute), Naomi Taylor(National Institutes of Health), Matthew J. Frank(Stanford Blood Center), Steven A. Feldman(Stanford University), Bonnie Yates(National Institutes of Health), Angela Su(Inserm), Kathryn R. Martin(University of Aberdeen), Sooraj Achar(Center for Cancer Research), Ramya Tunuguntla(Stanford University), Crystal L. Mackall(Stanford University), Dongya Jia(National Cancer Institute), Liora M. Schultz(Stanford Medicine), Anne Marijn Kramer(Stanford Blood Center), Bita Sahaf(Stanford University), Haneen Shalabi(Center for Cancer Research), David F. Stroncek(Yale University), Dorota D. Klysz(Stanford University), Nikeshan Jeyakumar(Stanford Blood Center), Zachary Ehlinger(Cancer Prevention Institute of California), Hao‐Wei Wang(Fu Jen Catholic University), Sunita Patil(Cancer Prevention Institute of California), Christopher D. Chien, Skyler Reitberg(Stanford University), Lori Muffly(Stanford University), Risa Ebina-Shibuya(Tohoku University), Steven L. Highfill(National Institutes of Health)
Cytotherapy
October 4, 2025
Cited by 1


Related Papers